Participación de las empresas

Tras el anuncio de la aprobación por parte de UNITAID de la expansión del mandato del Medicines Patent Pool a Hepatitis C y Tuberculosis en noviembre del 2015, el MPP firmó un acuerdo de licencia con Bristol-Myers Squibb (BMS) para el daclatasvir (DCV), tratamiento para la Hepatitis C. Mediante este acuerdo se permitirá la producción y distribución de genéricos de daclatasvir en un total de 112 países de renta baja y media. Asimismo, recientemente el MPP ha comenzado a negociar con el fabricante egipcio Pharco Pharmaceuticals para el ravidasvir, un medicamento candidato para el tratamiento para la Hepatitis C.

Hasta abril del 2016, el Medicines Patent Pool firmó acuerdos de licencia con AbbVie, Bristol-Myers Squibb, Roche, Gilead Sciences, MSD, ViiV Healthcare, la Universidad de Liverpool y los Institutos Nacionales de la Salud de los Estados Unidos.

Boehringer-Ingelheim se encuentra en negociaciones con el Medicines Patent Pool  y Janssen está colaborando con el MPP para ayudar en el desarrollo de nuevos tratamiento pediátricos a través de la Iniciativa para el Tratamiento Pediátrico contra el VIH (PHTI).

El MPP también ha comenzado el proceso de concesión de sublicencias a fabricantes de medicamentos genéricos, de modo que puedan comenzar a fabricar medicamentos contra el VIH a un menor costo. Hasta el noviembre de 2016 el MPP había celebrado acuerdos de sublicencias con quince  empresas: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab y Zydus Cadila.

El MPP espera continuar el diálogo con todos los titulares de patentes pertinentes y los fabricantes de medicamentos genéricos y asociaciones para el desarrollo de productos que reúnen los requisitos, a fin de alcanzar la meta de aumentar el acceso a medicamentos para las personas que viven con el VIH en los países en desarrollo.

En el siguiente cuadro, se resume el estado actual del compromiso con los titulares de patentes, y con los fabricantes de medicamentos genéricos y las asociaciones para el desarrollo de productos.

Participación de titulares de patente (en inglès)

Patent Holder 2016 2015 2014 2013 2012 2011 2010
AbbVie Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014 In negotiations Not in negociations Not in negotiations

Reply received 26 January

Sent letter on 1 December
Boehringer-Ingelheim

BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

In negotiations In negotiations In negotiations In negotiations In negotiations

Reply received 19 January

Sent letter on 1 December 
Bristol-Myers Squibb Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013 Licence agreement for atazanavir signed in December 2013 In negotiations In negotiations

Reply received 26 January

Sent letter on 1 December
F. Hoffman-La Roche Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 In negotiations In negotiations Sent letter on 1 December
Gilead Sciences Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 Licence agreement signed in July 2011. Additional amendment made in July 2012 and November 2012 Licence agreement signed in July. Amendments made November 2011. In negotiationsReply received 14 February Sent letter on 1 December
Merck Sharp & Dohme (MSD) Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 In negotiations Not currently in negotiations Not currently in negotiations Not currently in negotiations. Reply received 28 January Sent letter on 1 December
Janssen Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Not currently in negotiations Not currently in negotiations Not currently in negotiations. J&J decision not to licence at this time Not currently in negotiations. Reply Received 31 January Sent letter on 1 December
Pharco Pharmaceuticals N/A N/A N/A N/A N/A N/A N/A
 Research-based university  N/A  N/A  N/A  N/A  N/A  N/A N/A
 US National Institutes of Health Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir

In negotiations

Licence agreement signed in September 2010 for darunavir

In negotiations

 Licence agreement signed in September 2010 for darunavir
ViiV Healthcare Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in February 2013 for abacavir In negotiations In negotiations Sent letter on 1 December

 

This page is also available in: Inglés, Francés